Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040898 · ClinicalTrials.gov registry record · Phase 2
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00040898: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00040898 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040898, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells. This may be an effective treatment following hepatic artery embolization. PURPOSE: Phase II trial to study the effectiveness of Sho-saiko-to following hepatic artery embolization in treating patients who have liver cancer.
Interventions
- DIETARY_SUPPLEMENT Sho-saiko-to
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Phase | Phase 2 |
What the finished NCT00040898 record still lists
NCT00040898 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Sho-saiko-to is the first listed.
NCT00040898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040898 about?
NCT00040898 is a clinical study titled "Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed". RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells. This may be an effective treatment following hepatic artery embolization. PURPOSE: Phase II trial to study the effectiven...
What is the current status of trial NCT00040898?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-01.
What interventions are being tested in trial NCT00040898?
The interventions under investigation include: Sho-saiko-to (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00040898?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia